TrippBio, a biotechnology company, is producing a patent-pending repurposed FDA-approved drug called TD213 intended for the treatment of viral infections, initially targeting COVID-19, it was reported on Monday.
TD213 is administered orally twice daily and works by halting the SARS-CoV-2 virus and the associated acute inflammatory response to the infection.
The firm has revealed positive interim data from the investigator-initiated study to evaluate the efficacy of the product in treating patients with confirmed mild-moderate COVD-19.
Dr Moti N. Ramgopal of Midway Immunology and Research Center conducted the study. Outpatients who tested positive using a validated SARS-CoV-2 RNA COVID-19 test were administered the product twice daily for 14 days and will be followed until day 28.
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Lighthouse Pharmaceuticals announces receipt of USD49.2m grant from NIA for LHP588 study
Bio-Thera and STADA expand biosimilars partnership to include tocilizumab
Shilpa Medicare secures approval for NAFLD therapy NorUDCA in India
Remegen's Telitacicept meets Sjogren's syndrome Phase III trial's primary endpoint
PainReform acquires majority stake in LayerBio to advance dropless cataract surgery therapy
Seragon launches Enlivien sleep and longevity optimiser
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
Fosun Pharma agrees XH-S004 overseas licensing deal
Novartis reports positive Phase III results for ianalumab in Sjögren's disease